Generelt lignede emtricitabins farmakokinetik hos HBV- inficerede forsøgspersoner den hos raske forsøgspersoner og hos HIV- inficerede forsøgspersoner.
In general, emtricitabine pharmacokinetics in HBV infected subjects were similar to those in healthy subjects and in HIV infected subjects.